FDA Approves First Oral PCSK9 Inhibitor for LDL Cholesterol Management

The Food and Drug Administration has approved Lipfendra (enlicitide), a once-daily oral medicine intended to reduce low-density lipoprotein (LDL) cholesterol in adults who need additional lowering beyond existing measures.

Officials said the product is the first PCSK9 inhibitor cleared as a pill, creating a non-injectable option within a class that has previously relied on shots for delivery.

Lipfendra’s indication and how it is used

According to the approval details, Lipfendra is indicated as an adjunct to diet and statin therapy for adults requiring extra LDL cholesterol management.

The authorization places the drug alongside commonly used cholesterol approaches rather than as a standalone replacement, with use tied to ongoing dietary efforts and background statin treatment.

Trial results reported over 24 weeks

Clinical studies enrolling more than 3,200 participants showed substantial LDL reductions during the evaluation period.

Data from those trials found LDL cholesterol fell by about 56% to 59% over 24 weeks, supporting the drug’s ability to lower LDL levels, officials said.

Cardiovascular outcomes data remains an open question

While the trials validated LDL-lowering, the available information does not yet establish whether Lipfendra reduces clinical events such as heart attacks or strokes.

Officials said longer-term evidence on cardiovascular outcomes is still pending further study, leaving an important aspect of real-world benefit to be clarified beyond the measured cholesterol changes.

Pricing and expected pharmacy rollout

The manufacturer has set a list price of $10.50 per day and said the medication should reach pharmacies within weeks.

Patient out-of-pocket costs are expected to vary based on individual insurance coverage, the company said, adding that coupon programs are planned for commercially insured patients.

How quickly the new pill is adopted may depend on insurer decisions and patient affordability, given that list pricing and coverage terms do not always translate into the same costs at the pharmacy counter.